Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Antibody and Anlotinib in Recurrent or Advanced Endometrial Cancer
NCT04157491Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in endometrial cancer (EC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04157491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157491.